Phil Nickson, Ph.D.

Phil Nickson, Ph.D.

Chief Business and Legal OfficeratMonte Rosa Therapeutics· In proxies 2023–2025

Pay in FY2025+51% from the year before · Monte Rosa Therapeutics stock +125.9% the same year

Phil Nickson, Ph.D. was paid $1.9M in FY2025 (Dec), up 51%. Monte Rosa Therapeutics stock rose 125.9% that year.

Pay$100 in the stock at the end of FY22 → $206
Pay is from the Summary Compensation Table of each Monte Rosa Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Monte Rosa TherapeuticsPublic company · 3 yr
    • Chief Business and Legal Officer2023 – Present · 3 yrStock in role +60%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?